Loading patent…
OwnerRichard Glenn Wunderink, Grant William Watererinventors
Estimating the term…
This invention relates to diagnostic methods based upon a particular genotype in the Tumor Necrosis Factor (TNFα) gene, more specifically, GA or AA at the −238 site rather than the GG at this locus. More specifically, this invention relates to a method for diagnosis of increased risk of death in patients with community-acquired pneumonia (CAP) and diagnosing pre-disposition or susceptibility to increased risk of death in patients who develop CAP, by screening for the presence of this polymorphism. The invention also relates to compositions for screening for the polymorphism and improved treatment choices for patients having the polymorphism of the present invention. The invention also relates to screening assays and therapeutic and prophylactic methods.
A method of identifying an individual at an increased risk of death from community-acquired pneumonia (CAP) associated with the A allele in a TNFα gene at the −238 locus, said method comprising determining the genotype of said TNFα gene in an individual;
A method of treating patients comprising identifying a patient at an increased risk of death from community-acquired pneumonia (CAP) by identifying the A allele in a TNFα gene at the −238 locus in such patient;
Dependencies are inferred from the claim text.